Regulus Therapeutics Inc. (NASDAQ:RGLS) was the target of a significant decrease in short interest in the month of June. As of June 30th, there was short interest totalling 2,420,285 shares, a decrease of 43.5% from the June 15th total of 4,283,850 shares. Based on an average daily volume of 904,357 shares, the days-to-cover ratio is presently 2.7 days. Approximately 6.1% of the shares of the stock are sold short.

Regulus Therapeutics (NASDAQ RGLS) opened at 1.03 on Monday. Regulus Therapeutics has a 52 week low of $0.86 and a 52 week high of $4.25. The firm’s 50-day moving average price is $1.27 and its 200 day moving average price is $1.58. The firm’s market cap is $54.78 million.

Hedge funds have recently added to or reduced their stakes in the company. South Dakota Investment Council increased its stake in Regulus Therapeutics by 16.3% in the first quarter. South Dakota Investment Council now owns 1,327,058 shares of the biopharmaceutical company’s stock worth $2,190,000 after buying an additional 186,130 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Regulus Therapeutics by 13.5% in the first quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock worth $1,291,000 after buying an additional 93,295 shares during the period. Wedbush Securities Inc. boosted its position in shares of Regulus Therapeutics by 106.8% in the first quarter. Wedbush Securities Inc. now owns 180,921 shares of the biopharmaceutical company’s stock worth $299,000 after buying an additional 93,420 shares during the period. Tudor Investment Corp ET AL boosted its position in shares of Regulus Therapeutics by 131.5% in the first quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 61,373 shares during the period. Finally, A.R.T. Advisors LLC boosted its position in shares of Regulus Therapeutics by 405.0% in the fourth quarter. A.R.T. Advisors LLC now owns 90,400 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 72,500 shares during the period. Institutional investors own 38.56% of the company’s stock.

Several research firms recently weighed in on RGLS. Chardan Capital cut their price objective on shares of Regulus Therapeutics from $5.00 to $2.50 and set a “buy” rating for the company in a research report on Tuesday, June 13th. Wedbush reissued an “ourperform” rating and set a $6.00 target price on shares of Regulus Therapeutics in a research note on Tuesday, June 13th. BMO Capital Markets reissued a “hold” rating on shares of Regulus Therapeutics in a research note on Monday, May 15th. ValuEngine downgraded Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Zacks Investment Research raised Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a research note on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $3.92.

WARNING: “Regulus Therapeutics Inc. (RGLS) Short Interest Update” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/17/regulus-therapeutics-inc-rgls-short-interest-update.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.